Amarin Review PUBLISHED Inadvertently and 4 Stocks that Have Soared to 52-Week Highs

American Electric (NYSE:AEP): Some important companies who reported before the opening bell are American Electric Power (NYSE:AEP), Baker Hughes (NYSE:BHI), First Horizon National (NYSE:FHN), General Electric (NYSE:GE), Ingersoll-Rand (NYSE:IR), Schlumberger (NYSE:SLB), SunTrust Banks (NYSE:STI), and Xerox (NYSE:XRX). The shares closed at $42.00, up $0.09 or 0.21% on the day. They have traded in a 52-week range of $33.09 to $41.99.

Don’t Miss: GE Quarterly Earnings Sneak Peek.

Amgen Inc. (NASDAQ:AMGN) assisted BioPharma (NASDAQ:ARRY) in achieving its $8.5 million milestone. Array entered into the agreement with Amgen in December 2009 for the global development of the small-molecule glucokinase activator program, including AMG 151. The achievement of the milestone came after the AMgen gained a pre-defined patient enrollment  level in a Phase 2a clinical trial. The trial is a randomized, double-blind, placebo-controlled AMG 151 study combined with metformin in Type 2 diabetes patients. The main endpoint is a transformation in fasting plasma glucose levels from baseline to the completion of treatment. Amgen still pushes the trial and hopes to enroll around 224 patients. Array also is able to gain nearly $658 million in more aggregate milestone payments for the drug and a minimum of one backup compound. Array will also obtain royalties on the sales of any drug which has been approved under the agreement. The shares closed at $79.64, up $0.02 or 0.03% on the day. They have traded in a 52-week range of $47.66 to $79.90.

Amarin Corporation (NASDAQ:AMRN) revealed in a filing that information in relations to AMR101, the lead product candidate for Amarin Corp., along with its pending U.S. Food and Drug Administration regulatory review which was pending has been published via a draft website which was under design by third parties for Amarin. The information is not up to date and should not be taken as accurate, as the review is still pending at the FDA. The FDA has not made determinations on the AMR101 New Drug Application. The company states that it intends to announce news in relation to the final FDA determination on the  pending AMR101 NDA when appropriate. The target date for the FDA’s review is July 26. The Fly mentions that Amarin’s share strength has been attributed to the accidental posting. The shares closed at $15.36, up $0.7 or 4.77% on the day. They have traded in a 52-week range of $5.99 to $15.60.

Autonation (NYSE:AN) has a remaining balance of $368 million for share repurchasing. The shares closed at $40.78, down $1.67 or 3.93% on the day. They have traded in a 52-week range of $30.46 to $42.84.

Array Biopharma Inc. (NASDAQ:ARRY): Array BioPharma (NASDAQ:ARRY) announced that an $8.5M milestone was achieved in its collaboration with Amgen (NASDAQ:AMGN). Array entered into an agreement with Amgen in December 2009 for the worldwide development of the small-molecule glucokinase activator program, including AMG 151. The milestone was achieved after Amgen reached a pre-defined patient enrollment level in a Phase 2a clinical trial. The Phase 2a trial is a randomized, double-blind, placebo-controlled study of AMG 151 in combination with metformin in patients with Type 2 diabetes. The primary endpoint is change in fasting plasma glucose levels from baseline to end of treatment. Amgen continues to advance the trial and seeks to enroll approximately 224 patients. Under the agreement, Amgen paid an up-front fee of $60M. Array is also entitled to receive up to approximately $658 million in additional aggregate milestone payments if all clinical and commercialization milestones specified in the agreement for AMG 151 and at least one backup compound are achieved. Array will also receive royalties on sales of any approved drugs developed under the agreement.

Array Biopharma Inc. (NASDAQ:ARRY) announced an $8.5 million milestone has been achieved with its Amgen (NASDAQ:AMGN) collaboration. The company began the agreement in December 2009 for the global development of the small-molecule glucokinase activator program, including AMG 151. The milestone was came after the AMgen gained a pre-defined patient enrollment  level in a Phase 2a clinical trial. The trial is a randomized, double-blind, placebo-controlled AMG 151 study combined with metformin in Type 2 diabetes patients. The main endpoint is a transformation in fasting plasma glucose levels from baseline to the completion of treatment. Amgen still pushes the trial and hopes to enroll around 224 patients. Array also is able to gain nearly $658 million in more aggregate milestone payments for the drug and a minimum of one backup compound. Array will also obtain royalties on the sales of any drug which has been approved under the agreement. The shares closed at $79.64, up $0.02 or 0.03% on the day. They have traded in a 52-week range of $47.66 to $79.90.The shares closed at $4.02, up $0.03 or 0.75% on the day. They have traded in a 52-week range of $1.58 to $4.10.

Don’t Miss: GE Quarterly Earnings Sneak Peek.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.